ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases announced that Dan Mitchell has been appointed to the Company’s Board of Directors. Arca Biopharma Inc. (NASDAQ:ABIO) stock performance was -2.31% in last session and finished the day at $2.11. Traded volume was 3.15 million shares in the last session and the average volume of the stock remained 862,287.00 shares. The beta of the stock remained 2.84. Arca Biopharma Inc. (NASDAQ:ABIO) insider ownership is 3.40%.

Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galena Biopharma, Inc. (NASDAQ:GALE) has filed a federal securities fraud class action. Galena Biopharma Inc. (NASDAQ:GALE) dropped -7.08% to $3.02 yesterday on volume of 10.18 million shares. The intra-day range of the stock was $2.90 – $3.31. Galena Biopharma Inc. (NASDAQ:GALE) has a market capitalization of 263.71 million.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its results of operations for the fourth quarter and year-end 2013. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)’s stock on March 13, 2014 reported a lower of -4.80% to the closing price of $4.36. Its fifty two weeks range is $3.13 – $7.45. The total market capitalization recorded 264.21 million. The overall volume in the last trading session was 1.97 million shares. In its share capital, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has 60.60 million outstanding shares.

AVEO Pharmaceuticals logo AVEO Pharmaceuticals (NASDAQ:AVEO) announced its earnings results on Thursday. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. On Thursday, shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) dropped -4.74% to close the day at $1.81. Company return on investment (ROI) is -77.00% and its monthly performance is recorded as 3.43%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly revenue growth is -9.50%.